Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
43.54 (1y: +24%)
Market Cap 68.12 B P/E(ttm) 72.50
Enterprise Value 75.67 B P/B 20.40
Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry		 vs
history
Cash to Debt 0.509
ABBV's Cash to Debt is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ABBV: 0.509 )
ABBV' s 10-Year Cash to Debt Range
Min: 0.51   Max: No Debt
Current: 0.51
Equity to Asset 0.125
ABBV's Equity to Asset is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ABBV: 0.125 )
ABBV' s 10-Year Equity to Asset Range
Min: 0.13   Max: 0.62
Current: 0.13
0.13
0.62
Interest Coverage 69.3
ABBV's Interest Coverage is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ABBV: 69.3 )
ABBV' s 10-Year Interest Coverage Range
Min: 69   Max: No Debt
Current: 69.3
Z-Score: 3.46
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry		 vs
history
Operating margin (%) 31.60
ABBV's Operating margin (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ABBV: 31.60 )
ABBV' s 10-Year Operating margin (%) Range
Min: 20.8   Max: 34.7
Current: 31.6
20.8
34.7
Net-margin (%) 28.7
ABBV's Net-margin (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ABBV: 28.7 )
ABBV' s 10-Year Net-margin (%) Range
Min: 19.7   Max: 32.6
Current: 28.7
19.7
32.6
ROE (%) 156.9
ABBV's ROE (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ABBV: 156.9 )
ABBV' s 10-Year ROE (%) Range
Min: 28.1   Max: 156.9
Current: 156.9
28.1
156.9
ROA (%) 19.5
ABBV's ROA (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ABBV: 19.5 )
ABBV' s 10-Year ROA (%) Range
Min: 17.5   Max: 19.5
Current: 19.5
17.5
19.5
ROC (Joel Greenblatt) (%) 149.50
ABBV's ROC (Joel Greenblatt) (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ABBV: 149.50 )
ABBV' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 122.8   Max: 149.5
Current: 149.5
122.8
149.5
» ABBV's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

ABBV Guru Trades in

Q3 2012

ABBV Guru Trades in Q3 2012

Jim Simons 321,100 sh (unchged)
John Buckingham 91,691 sh (unchged)
Dodge & Cox 38,063 sh (unchged)
Pioneer Investments 3,401,398 sh (unchged)
Mason Hawkins 7,949,000 sh (unchged)
Tom Russo 104,550 sh (unchged)
Bill Frels 215,022 sh (unchged)
Diamond Hill Capital 3,614,531 sh (unchged)
Robert Bruce 234,800 sh (unchged)
Vanguard Health Care Fund 12,100,000 sh (unchged)
PRIMECAP Management 4,559,547 sh (unchged)
Donald Yacktman 3,000 sh (unchged)
Paul Tudor Jones 3,500 sh (unchged)
Richard Pzena 2,218,879 sh (unchged)
Ronald Muhlenkamp 326,270 sh (unchged)
Jeff Auxier 80,540 sh (unchged)
Jeremy Grantham 14,436,509 sh (unchged)
Mario Gabelli 54,209 sh (unchged)
Manning & Napier Advisors, Inc 222,249 sh (unchged)
Joel Greenblatt 16,426 sh (unchged)
John Hussman 501,000 sh (unchged)
George Soros 200,000 sh (unchged)
Scott Black 32,685 sh (unchged)
Murray Stahl 37,392 sh (unchged)
Meridian Funds 9,400 sh (unchged)
Steven Cohen 620,343 sh (unchged)
Westport Asset Management 67,500 sh (unchged)
» More
Q4 2012

ABBV Guru Trades in Q4 2012

Daniel Loeb 416,000 sh (New)
Paul Tudor Jones 250,000 sh (+7042.86%)
Steven Cohen 1,518,654 sh (+144.81%)
Ken Fisher 238,339 sh (unchged)
Ronald Muhlenkamp Sold Out
George Soros Sold Out
Diamond Hill Capital Sold Out
Donald Yacktman Sold Out
Dodge & Cox Sold Out
Scott Black Sold Out
John Buckingham Sold Out
PRIMECAP Management Sold Out
Bill Frels Sold Out
Murray Stahl Sold Out
Manning & Napier Advisors, Inc Sold Out
Joel Greenblatt Sold Out
Jeff Auxier Sold Out
Mario Gabelli Sold Out
Richard Pzena Sold Out
Pioneer Investments Sold Out
Jim Simons Sold Out
Robert Bruce 234,300 sh (-0.21%)
Vanguard Health Care Fund 1,645,000 sh (-86.4%)
Mason Hawkins 6,000 sh (-99.92%)
» More
Q1 2013

ABBV Guru Trades in Q1 2013

Pioneer Investments 2,245,343 sh (New)
John Hussman 403,250 sh (New)
Westport Asset Management 180,000 sh (New)
Joel Greenblatt 37,488 sh (New)
Dodge & Cox 37,865 sh (New)
Jim Simons 2,427,900 sh (New)
Jeff Auxier 80,440 sh (New)
PRIMECAP Management 5,991,647 sh (New)
Murray Stahl 33,628 sh (New)
Mario Gabelli 15,780 sh (New)
John Buckingham 80,359 sh (New)
George Soros 331,852 sh (New)
Manning & Napier Advisors, Inc 226,328 sh (New)
Bill Frels 271,533 sh (New)
Tom Russo 88,250 sh (New)
Vanguard Health Care Fund 14,151,000 sh (+760.24%)
Daniel Loeb 2,950,000 sh (+609.13%)
Paul Tudor Jones 800,000 sh (+220%)
Ken Fisher 446,893 sh (+87.5%)
Robert Bruce 234,300 sh (unchged)
Mason Hawkins Sold Out
Steven Cohen 1,152,695 sh (-24.1%)
» More
» Details

Insider Trades

Latest Guru Trades with ABBV

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2013-03-31 Add 760.24%2.03%$33.71 - $40.78 $ 43.5418%14151000
Daniel Loeb 2013-03-31 Add 609.13%1.98%$33.71 - $40.78 $ 43.5418%2950000
John Hussman 2013-03-31 New Buy0.6%$33.71 - $40.78 $ 43.5418%403250
PRIMECAP Management 2013-03-31 New Buy0.36%$33.71 - $40.78 $ 43.5418%5991647
George Soros 2013-03-31 New Buy0.16%$33.71 - $40.78 $ 43.5418%331852
Joel Greenblatt 2013-03-31 New Buy0.08%$33.71 - $40.78 $ 43.5418%37488
Dodge & Cox 2013-03-31 New Buy$33.71 - $40.78 $ 43.5418%37865
Mason Hawkins 2013-03-31 Sold Out $33.71 - $40.78 $ 43.5418%0
Mario Gabelli 2013-03-31 New Buy$33.71 - $40.78 $ 43.5418%15780
Daniel Loeb 2012-12-31 New Buy0.26%$33 - $35.35 $ 43.5427%416000
George Soros 2012-12-31 Sold Out $33 - $35.35 $ 43.5427%0
Ronald Muhlenkamp 2012-12-31 Sold Out $33 - $35.35 $ 43.5427%0
Mario Gabelli 2012-12-31 Sold Out $33 - $35.35 $ 43.5427%0
Scott Black 2012-12-31 Sold Out $33 - $35.35 $ 43.5427%0
Vanguard Health Care Fund 2012-12-31 Reduce -86.4%$33 - $35.35 $ 43.5427%1645000
Donald Yacktman 2012-12-31 Sold Out $33 - $35.35 $ 43.5427%0
Dodge & Cox 2012-12-31 Sold Out $33 - $35.35 $ 43.5427%0
Joel Greenblatt 2012-12-31 Sold Out $33 - $35.35 $ 43.5427%0
Mason Hawkins 2012-12-31 Reduce -99.92%$33 - $35.35 $ 43.5427%6000
PRIMECAP Management 2012-12-31 Sold Out $33 - $35.35 $ 43.5427%0
Premium More recent guru trades are included for Premium Members only!!
» Financial Charts

Peter Lynch Chart

Top Ranked Articles about AbbVie Inc

Daniel Loeb's Top Three Increases of the First Quarter
May 24, 2013
Daniel Loeb - Daniel Loeb's Top Three Increases Of The First Quarter
Billionaire Daniel Loeb of Third Point LLC has a portfolio consisting of 40 stocks, 12 of those being new buys, valued at $5.3 billion. Loeb is well known in the financial world for writing public letters in which he expresses disapproval of the performance and conduct of other financial executives. In 2012 the guru reported a return of 21.2%, an excess gain of 5.8% over the S&P 500’s return. Read more...
Mason Hawkins Gives Mickey Mouse the Boot, First Quarter Sells in Review
May 15, 2013
Mason Hawkins - Mason Hawkins Gives Mickey Mouse The Boot, First Quarter Sells In Review
Demonstrating once again that emotion can never get in the way of investing decisions, Guru Mason Hawkins of Southeastern Asset Management determined in the first quarter of 2013 that, as the Mickey Mouse Club once sang, “Now it’s time to say goodbye.” Hawkins let go of Mickey Mouse and other timeless icons of entertainment when he sold out his long-held stake in Walt Disney Co., as well as seven more companies. Read more...
Weekly 52 Week Highs: ABBV, ABT, YUM, AET
February 11, 2013
According to GuruFocus Insider Data, these are the largest insider buys during the past week: AbbVie Inc. (ABBV), Abbot Laboratories (ABT), Yum! Brands Inc. (YUM), and Aetna Inc. (AET). Read more...

Ratios

vs
industry		 vs
history
P/E(ttm) 72.50
ABBV's P/E(ttm) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ABBV: 72.50 )
ABBV' s 10-Year P/E(ttm) Range
Min: 62.23   Max: 78.62
Current: 72.5
62.23
78.62
P/B 20.40
ABBV's P/B is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ABBV: 20.40 )
ABBV' s 10-Year P/B Range
Min: 20.2   Max: 25.64
Current: 20.4
20.2
25.64
P/S 3.70
ABBV's P/S is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ABBV: 3.70 )
ABBV' s 10-Year P/S Range
Min: 3.7   Max: 17.47
Current: 3.7
3.7
17.47
PFCF 63.80
ABBV's PFCF is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ABBV: 63.80 )
ABBV' s 10-Year PFCF Range
Min: 54.91   Max: 69.37
Current: 63.8
54.91
69.37
EV-to-EBIT 12.3
ABBV's EV-to-EBIT is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ABBV: 12.3 )
ABBV' s 10-Year EV-to-EBIT Range
Min: 11   Max: 13.6
Current: 12.3
11
13.6

Dividend & Buy Back

vs
industry		 vs
history
Dividend Yield 1.90
ABBV's Dividend Yield is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ABBV: 1.90 )
ABBV' s 10-Year Dividend Yield Range
Min: 0.85   Max: 1.07
Current: 1.9
0.85
1.07
Dividend Payout 0.1182
ABBV's Dividend Payout is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ABBV: 0.1182 )
ABBV' s 10-Year Dividend Payout Range
Min: 0   Max: 0
Current: 0.12
Yield on cost (5-Year) 1.90
ABBV's Yield on cost (5-Year) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ABBV: 1.90 )
ABBV' s 10-Year Yield on cost (5-Year) Range
Min: 0.85   Max: 1.07
Current: 1.9
0.85
1.07

Valuation & Return

vs
industry		 vs
history
Price/Net Current Asset Value 18.3
ABBV's Price/Net Current Asset Value is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ABBV: 18.3 )
ABBV' s 10-Year Price/Net Current Asset Value Range
Min: 14.4   Max: 14.4
Current: 18.3
Price/Median PS Value 1
ABBV's Price/Median PS Value is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ABBV: 1 )
ABBV' s 10-Year Price/Median PS Value Range
Min: 0   Max: 0
Current: 1
Earnings Yield (Greenblatt) 8.10
ABBV's Earnings Yield (Greenblatt) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ABBV: 8.10 )
ABBV' s 10-Year Earnings Yield (Greenblatt) Range
Min: 7.4   Max: 9.1
Current: 8.1
7.4
9.1

Business Description


Company Website
SEC Reports
Industry:
Compare:
Traded in other countries:ABBV.Switzerland, ABBV.France, 4AB.Germany
» More Articles for ABBV

Headlines

Articles On GuruFocus.com
5 Quality Dividend Stocks to Take the Emotion out of Investing Jun 11 2013 
comment on ABBV May 25 2013 
comment on ABBV May 25 2013 
Daniel Loeb's Top Three Increases of the First Quarter May 24 2013 
Johnson & Johnson (JNJ) Dividend Stock Analysis May 23 2013 
Mason Hawkins Gives Mickey Mouse the Boot, First Quarter Sells in Review May 15 2013 
Dodge & Cox Buys Kraft and AbbVie May 14 2013 
comment on ABBV Apr 25 2013 
Abbvie Inc. (ABBV) Dividend Stock Analysis Mar 22 2013 
10 Best Dividend Paying Drug Manufacturing Stocks Mar 02 2013 

More From Our Partners
Data on BMY/ AbbVie's elotuzumab - Analyst Blog Jun 17 2013 - ZACKS

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK